Semaglutide (STEP trials) In the landmark STEP 1 trial, participants on semaglutide 2.4 mg weekly lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% for placebo
Expanding options for optimizing type 2 diabetes treatment As the treatment landscape for type 2 diabetes continues to evolve, the findings from the SURPASS-SWITCH trial offer timely insight for clinicians managing patients who are not achieving glycemic or weight-related goals with their current GLP-1 receptor agonist regimen
10.3390/biology13110945 91 PetrovM
If your daily routine or travel makes refrigeration or room temperature storage difficult, using a medical-grade portable cooler can help you maintain safe storage without interruption
Now, the real-world use is broader, messierand more revealing
The JAMA article mentioned above recognizes that during such situations the anesthesiologist and surgeon must take special precautions to avoid aspiration